Login to Your Account



BioMarin's Second MPS Drug, Naglazyme, Approved By FDA

By Jennifer Boggs


Thursday, June 2, 2005
BioMarin Pharmaceutical Inc. is wasting little time getting to the market with its newly approved enzyme-replacement therapy, Naglazyme, for patients with mucopolysaccharidosis VI. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription